|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two out of the four p53(wt) relapsing breast cancer patients showed the Arg72Pro allelic variant; one of these died at 75 months.
|
12702523 |
2003 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study implies an association of breast cancer risk with the p53 polymorphism Arg72Pro, but not with p73 G4A.
|
14634508 |
2003 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.
|
15138483 |
2004 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele distribution of the R72P missense mutation between ethnically diverse Jewish breast cancer cases and average risk controls showed significant differences: among non-Ashkenazi breast cancer cases, 62.5%, 33.3% and 4.2% were homozygous, heterozygous and homozygous for the Arg72, Arg72Pro and the Pro72 polymorphism, respectively, whereas for controls, the distribution was 22.4%, 65.4% and 12.2%, respectively (P=0.00052), and among Ashkenazi breast cancer cases, allele distribution was 68.5%, 29.6% and 1.9%, whereas for controls, the distribution was 50%, 40% and 10%, respectively (P=0.0125).
|
15756275 |
2005 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results suggest no effect of either R72P allele on breast cancer risk but a significantly reduced survival for 72P homozygous breast cancer patients.
|
16033823 |
2005 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, we found a significant gene-gene interaction between P53BP1 Gln1136Lys and p53 Arg72Pro variants in relation to breast cancer, and the OR of interaction for the presence of both P53BP1 1136Gln/Lys+Lys/Lys and p53 72Arg/Pro+Pro/Pro genotypes was 1.93 (95% CI 1.06-3.52) (P=0.031 for interaction).
|
16314399 |
2006 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies.
|
17387621 |
2007 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We evaluated whether three well-characterized TP53 variants -- Ex4 + 119 C > G (rs#1042522, Arg72Pro), IVS6 + 62 A > G (rs#1625895), and an IVS3 16 bp insertion/ deletion (INDEL; rs#17878362) -- were associated with breast cancer risk in a population-based case-control study.
|
17624591 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India.
|
17696741 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Neither combined nor homozygous/heterozygous MDM-2 SNP309G was associated with total, premenopausal, or postmenopausal breast cancer risk; however, MDM-2 SNP309G, along with p53 Arg72Pro heterozygous variant, showed a significant protective association with premenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.18 [0.02-1.20], p value; 0.041 for homozygous + heterozygous MDM-2 SNP309G).
|
17719241 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.
|
17909070 |
2007 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
|
18058229 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The purpose of this study was to evaluate the role of Arg72Pro and PIN3 Ins16bp polymorphisms in TP53 gene as genetic susceptibility and predictive markers to breast cancer.
|
18230179 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TP53 polymorphisms Arg72Pro (Ex4+199 G>C) and Ins16 (IVS3+24 ins16) have been proposed to modify risk of breast cancer associated with germline BRCA1 and BRCA2 mutations.
|
18402691 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These observations suggested that neither the Ins16bp or Arg72Pro polymorphisms considered separately, nor any related haplotype, were associated with breast cancer risk in BRCA-mutation negative familial cases.
|
18640791 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Specifically, two polymorphisms in p53, c.97-147ins16bp and p.Arg72Pro have been analysed as putative breast cancer susceptibility variants, and it has been recently reported that a p53 haplotype combining the absence of the 16-bp insertion and the presence of proline at codon 72 (No Ins-72Pro) was associated with an earlier age at the onset of the first primary tumour in BRCA2 mutation carriers in the Spanish population.
|
18781154 |
2008 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer.
|
19639206 |
2009 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
19707196 |
2009 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We pooled data from four breast cancer cohorts within the Breast Cancer Association Consortium for which both TP53 R72P and MDM2 SNP309 were genotyped and follow-up was available (n = 3,749).
|
20021639 |
2009 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
|
20127253 |
2010 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The present study was undertaken to investigate the association of p53 Arg72Pro, Ins16bp and G13964C polymorphisms and their haplotypes with breast cancer risk in Tunisian women.
|
20233677 |
2010 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The P53 gene codon 72 Arg/Pro and Her2 gene Ile655Val polymorphisms were not associated with the risk of breast cancer in Turkish women.
|
20380571 |
2010 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy.
|
20638924 |
2010 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Different genotypes of the Arg72Pro and PIN3 (+16 bp) polymorphisms had no significant impact on survival in breast cancer patients.
|
21365326 |
2012 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we investigated whether MDM2-SNP309 is associated with p53 R72P genetic polymorphism for the risk of breast cancer development in Asian Taiwanese, which has not been well-studied in this regard.
|
21479369 |
2011 |